| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Robert Langer is Director at MRNA, with reported holdings spanning 4 companies. Robert Langer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.6B at current prices.
Robert Langer's largest disclosed position is in MRNA as Director, worth about $2.6B.
Robert Langer has 22 Form 4 filings on record from July 2017 to July 2026, across 5 companies: Director at Seer (SEER), 2020–2026; Director at Moderna (MRNA), 2021–2024; Director at Korro Bio (KRRO), 2020–2022, and 2 more.
The 31 reported transactions were 19 option or other derivative awards, 5 stock awards, 3 conversions and 2 dispositions back to the company, plus smaller numbers of other types.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria